36 is the current PE of CSL ( biggest biotech on asx ) , and just happens to be same PE for reoccurring royalties for Nuren. Asx bio startup ( like botanix ) that recieved fda clearance recently.
It could just be a fluke they are both 36, but what a coincidence. I only looked at those two. CSL for what investors value a long term solid , slow growth medical vs short term startup ( Nuren ) with first product just in market, so 36 PE is what the evidence points towards in my opinion.
The big unknown, is the E ?
Currently priced at around 3000 patients for 1 year, or 36,000 patients for a 1 off 1 month buy.
36 is the current PE of CSL ( biggest biotech on asx ) , and...
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $581.5M | |||
| Open | High | Low | Value | Volume |
| 33.5¢ | 34.8¢ | 32.0¢ | $3.160M | 9.427M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 670399 | 32.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.5¢ | 24177 | 3 |
View Market Depth
| Last trade - 16.10pm 14/11/2024 (20 minute delay) ? |
| BOT (ASX) Chart |